MSMathias Stroobants

Mathias Stroobants

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mathias Stroobants has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inhibition of SMYD3 Alleviates Cognitive Impairment in a Mouse Model of Hypertension-Driven cSVD Disease by Improving Endothelial Dysfunction

    by Xiaoyu Liang, Zsuzsanna Callaerts-Végh, Raj Sewduth, Mathias Stroobants, Marleen Lox, Anna Sablina, Dietmar Rudolf Thal, Elizabeth Jones

    Hypertension-driven vascular remodelling and endothelial dysfunction are key pathological processes underlying cerebral small vessel disease (cSVD), a leading cause of vascular cognitive impairment. Although extracellular matrix (ECM) remodelling is a critical regulator of endothelial behaviour, its mechanistic contribution to hypertension-associated cSVD remains poorly understood. Here, we identify a conserved, disease-associated shift in vascular ECM composition across human vascular dementia datasets and the DOCA-salt model of hypertension, marked by pronounced perivascular accumulation of type I collagen (COL1). Given that hypertension-induced cSVD is characterised by cerebral hypoperfusion, we investigated how ECM remodelling modulates endothelial mechanotransduction under low-flow conditions. Human brain microvascular endothelial cells cultured on COL1 under low shear stress (5 dyn/cm²) exhibited a striking loss of Transforming Growth Factor-β–Activated Kinase 1 (TAK1), accompanied by suppression of NF-κB signaling. In contrast, fibronectin (FN1) preserved TAK1 stability and activation. Consistently, TAK1 expression was markedly reduced in cerebral microvessels from hypertensive mice and post-mortem brains of individuals with cSVD. Mechanistically, we demonstrate that COL1 promotes SMYD3-dependent, proteasome-mediated degradation of TAK1. Genetic or pharmacological inhibition of SMYD3 prevented TAK1 loss, restored NF-κB signalling, improved endothelial junction integrity, and enhanced nitric oxide bioavailability under low shear conditions. Notably, SMYD3 expression was elevated in both experimental and human cSVD. Importantly, SMYD3 inhibition in vivo ameliorated cognitive deficits in hypertensive mice. Together, these findings identify ECM remodelling as a critical determinant of endothelial signaling dysfunction in cSVD and uncover a previously unrecognised SMYD3–TAK1 axis linking mechanical and inflammatory pathways. Targeting SMYD3 to preserve TAK1 signalling represents a promising therapeutic strategy to restore vascular integrity and prevent hypertension-associated cognitive decline.

  • Anakinra restores immunological misfiring that drives influenza-associated pulmonary aspergillosis

    by Laura Seldeslachts, Sirima Kraisin, Intan M. W. Dewi, Simon Feys, Frederik Staels, Marina Gkountzinopoulou, Cato Jacobs, Birger Tielemans, Eliane Vanhoffelen, Agustin Reséndiz-Sharpe, et al.

    Influenza-associated pulmonary aspergillosis (IAPA) is a severe fungal superinfection affecting critically ill patients with influenza. Current treatments target the causative pathogens but do not address the dysregulated host immune responses that drive morbidity. Host-directed immunotherapies could overcome this treatment gap. Here, we studied the host-pathogen factors driving IAPA using patient samples and an IAPA mouse model. We identified interleukin-1 (IL-1)–mediated inflammation, neutrophil activation, and neutrophil extracellular trap (NET) release as crucial features in IAPA pathogenesis. This inflammation led to an immunological imbalance with defective neutrophil effector functions, including impaired reactive oxygen production (ROS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, thereby impairing the fungal host immune response toward a permissive environment for Aspergillus fumigatus . Blocking the IL-1 receptor with anakinra reduced inflammation and NET release, restored ROS production in neutrophils, and rescued influenza virus–infected mice from invasive pulmonary aspergillosis. Our findings underscore the crucial role of IL-1–driven inflammation in the immunological misfiring that drives IAPA and suggest anakinra as a promising immunomodulatory therapy for patients with IAPA.


  • Open Access

    Neutrophil Extracellular Traps and Delayed Cerebral Ischemia in Patients With Subarachnoid Hemorrhage

    by Hauke Schneider, Diana Münch, Valérie Spalart, Mathias Stroobants, Ansgar Berlis, Christoph J. Maurer, Ulrich Jaschinski, Scott E. Kasner, Quy Cao, Kimberly Martinod, et al.

    Background: Delayed cerebral ischemia (DCI) after spontaneous subarachnoid hemorrhage (SAH) is not well understood. Recent studies suggest the involvement of neutrophil‐mediated immunothrombosis via neutrophil extracellular traps (NETs). We aimed to assess whether trajectories of NET biomarkers in patients with acute SAH are associated with DCI. Methods: This was a prospective single‐center study of patients within 48 hours of SAH onset. We collected clinical, laboratory, imaging, and 3‐month outcome data. NET markers (H3Cit [citrullinated histone H3]‐DNA complexes, myeloperoxidase‐DNA complexes, cell‐free DNA), along with peptidylarginine deiminase 4, and deoxyribonuclease activity were measured in plasma collected on admission (baseline), and post‐SAH days 5 and 10. DCI was defined by clinical and imaging criteria. Generalized estimating equations examined differences in NET trajectories comparing patients with and without DCI. Results: We enrolled 40 patients with SAH (mean age, 57 years; n=21 [53%] women; 32 [80%] aneurysmal). DCI occurred in 12 (30%) patients. All NET levels were similar between groups at baseline. On day 5, those with DCI compared with those without DCI had elevated median H3Cit‐DNA complex (63 ng/mL versus 31 ng/mL, P =0.049), myeloperoxidase‐DNA complex (5.9 ng/mL versus 0.4 ng/mL, P =0.029), and cell‐free DNA (651 ng/mL versus 515 ng/mL, P =0.04) levels, which trended back down on day 10. In the DCI group, generalized estimating equations indicated heightened trajectories of H3Cit‐DNA complex (day 5 [compared with baseline]: β=0.7; SE, 0.3; P =0.01; day 10: β=0.5; SE, 0.3; P =0.09), and myeloperoxidase‐DNA complex levels (day 5: β=3.1; SE, 0.4; P P =0.10). Conclusions: In patients with acute SAH, elevated plasma trajectories of NETs are associated with DCI.


  • CCR2+ monocyte-derived macrophages drive cardiac hypertrophy in early HFpEF

    by Jana Raman, Steven Simmonds, Ellen Caluwé, Rick van Leeuwen, Caroline Walschap, Mathias Stroobants, Ümare Cöl, Petra Vandervoort, Stephane Heymans, Elizabeth A. V. Jones

    Development of a multi-comorbidity model induces early heart failure with preserved ejection fraction (HFpEF) in male mice. Early HFpEF is marked by circulating proinflammatory monocytosis (Ly6Chi) and a disruption in the balance between monocyte-derived macrophage infiltration (CCR2+) and resident macrophages (TIMD4+). Ablation of CCR2, which prevents recruitment of classical macrophages, improves left ventricle (LV) hypertrophy in early HFpEF but not cardiac fibrosis or diastolic dysfunction. Anti-inflammatory therapies alone, without antifibrotic treatment, will likely not prevent the development of HFpEF.


  • Open Access

    PB0752 Platelet Peptidylarginine Deiminase 4 is Not Essential for Platelet Activation or Development of Cardiac Fibrosis in Mice

    by K. Bomhals, S. Kraisin, V. Spalart, S. Meyers, M. Stroobants, L. Frederix, K. Martinod

  • Neutrophil peptidylarginine deiminase 4 is essential for detrimental age-related cardiac remodelling and dysfunction in mice

    by Stijn Van Bruggen, Sirima Kraisin, Jore Van Wauwe, Katrien Bomhals, Mathias Stroobants, Paolo Carai, Liesbeth Frederix, Alexander Van De Bruaene, Thilo Witsch, Kimberly Martinod

    Mice fully deficient in peptidylarginine deiminase 4 (PAD4) enzyme have preserved cardiac function and reduced collagen deposition during ageing. The cellular source of PAD4 is hypothesized to be neutrophils, likely due to PAD4's involvement in neutrophil extracellular trap release. We investigated haematopoietic PAD4 impact on myocardial remodelling and systemic inflammation in cardiac ageing by generating mice with Padi4 deletion in circulating neutrophils under the MRP8 promoter (Ne-PAD4 −/− ), and ageing them for 2 years together with littermate controls (PAD4 fl/fl ). Ne-PAD4 −/− mice showed protection against age-induced fibrosis, seen by reduced cardiac collagen deposition. Echocardiography analysis of structural and functional parameters also demonstrated preservation of both systolic and diastolic function with MRP8-driven PAD4 deletion. Furthermore, cardiac gene expression and plasma cytokine levels were evaluated. Cardiac genes and plasma cytokines involved in neutrophil recruitment were downregulated in aged Ne-PAD4 −/− animals compared to PAD4 fl/fl controls, including decreased levels of C-X-C ligand 1 (CXCL1). Our data confirm PAD4 involvement from circulating neutrophils in detrimental cardiac remodelling, leading to cardiac dysfunction with old age. Deletion of PAD4 in MRP8-expressing cells impacts the CXCL1–CXCR2 axis, known to be involved in heart failure development. This supports the future use of PAD4 inhibitors in cardiovascular disease. This article is part of the Theo Murphy meeting issue ‘The virtues and vices of protein citrullination’.